IRSB - Iris BioTechnologies, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Iris BioTechnologies, Inc.

5201 Great America Parkway
Suite 320
Santa Clara, CA 95054
United States

IndustryMedical Instruments & Supplies
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. Simon S. M. Chin MBAFounder, Chairman, Chief Exec. Officer, Pres, Chief Financial Officer and Sec.N/AN/A1959
Mr. James LeBlanc MBAVP of OperationsN/AN/A1947
Dr. Paul Yaswen Ph.D.Chief Scientific OfficerN/AN/A1958
Ms. Grace Osborne MBAVP of Bus. Devel. & HR and DirectorN/AN/A1967
Dr. Ronald Mark Gemberling M.D.Chief Medical OfficerN/AN/A1947
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Iris BioTechnologies, Inc., a life science company, develops solutions for the detection and monitoring of monogenic and complex genomic diseases. It is developing nano-biochip technology platform used for the diagnosis and treatment of patients with breast cancer, neurological disorders, heart diseases, diabetes, and other gene-related metabolic problems. The company also develops BioWindows, an artificial intelligence system, which provides data and analysis for clinical applications, drug development, and stem cell research. Iris BioTechnologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.

Corporate Governance

Iris BioTechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.